quipazine has been researched along with oxymetazoline in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Conklin, DS; Fitzgerald, LW; Hartig, PR; Iyer, G; Kostich, WA; Krause, CM; Largent, BL; Marshall, AP; Patterson, JP; Tran, DP | 1 |
Hashim, A; Lajtha, A; Sershen, H | 1 |
2 other study(ies) available for quipazine and oxymetazoline
Article | Year |
---|---|
High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action.
Topics: Amphetamines; Binding, Competitive; Cell Line; Ergolines; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Hydrolysis; Isomerism; Ligands; Models, Biological; Phosphatidylinositols; Receptors, Serotonin; Recombinant Proteins; Serotonin Antagonists; Serotonin Receptor Agonists; Spiperone | 1999 |
Serotonin-mediated striatal dopamine release involves the dopamine uptake site and the serotonin receptor.
Topics: Animals; Bicuculline; Cocaine; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; GABA Antagonists; Ketanserin; Male; Methiothepin; Mice; Mice, Inbred C57BL; Oxymetazoline; Piperazines; Quinoxalines; Quipazine; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 2000 |